Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS107E
- Development stage
- Phase 2
- Lead developer
- DS Biopharma
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical, Oral
01
Overview
DS107E is a topical pharmaceutical formulation containing dihomo-γ-linolenic acid (DGLA), a long-chain polyunsaturated fatty acid. It is developed as a cream for the treatment of mild to moderate atopic dermatitis. DS107E acts as an immunomodulating, bioactive lipid that targets immune activation and skin barrier dysfunction in atopic dermatitis by inhibiting the expression of CD40, which downregulates T-cell activation and reduces downstream Th2, Th1, Th17, and Th22 cytokine production. Additionally, DGLA metabolism via cyclooxygenase pathways leads to anti-inflammatory eicosanoids such as prostaglandins (notably PGD1) and thromboxanes. Clinical studies have shown that DS107E provides significant improvements in clinical endpoints like Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI-75), and pruritus scores with an excellent safety profile[2][4][6].
- Brand names
- galepa
- Other names
- DGLA cream
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on DS107E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS107E.